Trial result ·
Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This study tested tiomolibdate choline (TMC), a copper-binding drug taken by mouth. It was given to 9 people with Wilson disease, a rare copper disorder. This was a phase 2 trial, and everyone got the drug. People began in a research unit on a diet with set copper. Between days 9 and 24, they could leave but kept taking TMC. Staff measured copper taken in and copper passed in stool and urine.
What they found
Copper balance went down over the whole 39 days on TMC. This came from more copper leaving the body in the stool. The drop was fast and clear from day 4. Over 21 days, the average drop was 6.08 mg of copper. Blood copper rose right away, which fits copper being drawn into the blood. People handled TMC well, and alanine aminotransferase rises were mild and eased with dose changes.
What it means for patients
The authors say TMC lowered copper balance in people with Wilson disease. It also moved copper strongly into the blood. They say this backs TMC as a possible treatment for Wilson disease.
Why it is not certain yet
The trial had only 9 people. There was no comparison group, so all people got TMC. People and staff knew which drug was given. Treatment lasted only 39 days. An early-stage trial like this cannot show if the drug helps long term. The abstract does not report how symptoms changed.
Source
Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial.
PubMed · PMID 42155004We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Wilson disease publications